In the News
July 21, 2022
Fierce Biotech
Servier Takes Aim at US Oncology Market, Doubling R&D Lab Space in Boston
July 21, 2022
Boston Business Journal
Servier Unveils New Cancer-Focused Seaport R&D Campus
July 18, 2022
Boston Globe
More Lab Space: French Pharma Servier is Growing its Cancer Business in Seaport
July 16, 2022
Healthcare Digital Magazine
Creating Supply Chain Solutions in Oncology with Servier
May 26, 2022
Endpoints News
Servier Expands Tibsovo Label with First Combination OK in a Rare Form of AML
May 26, 2022
Fierce Pharma
Servier's Tibsovo Snags FDA Combo Nod in First-Line AML, Expanding Its Use in Tough-To-Treat Cancer
May 25, 2022
Cure Today
FDA Approves Tibsovo Plus Vidaza for Patients with Newly Diagnosed Acute Myeloid Leukemia
May 25, 2022
Targeted Oncology
FDA Approves Ivosidenib Plus Azacitidine for Previously Untreated IDH1-Mutated AML
December 12, 2021
Healio
Ivosidenib regimen extends OS, EFS for acute myeloid leukemia subset
December 11, 2021
Endpoints News
ASH: Servier unveils full dataset for Tibsovo in specific AML mutations, and the FDA appears a stone's throw away
December 11, 2021
Fierce Pharma
ASH: Servier's Tibsovo triumph in leukemia study primes med for combo use—and possibly Europe
December 11, 2021
Onco'Zine
Updated Data to be Presented at ASH Reinforces the Strength of Servier’s Hematology Portfolio
September 13, 2021
Cure Today
‘Landmark’ FDA Approval of Tibsovo May Improve Outcomes for Liver Cancer Subtype
September 1, 2021
Fierce Pharma
Servier's beefing up in oncology through dealmaking and Tibsovo wins—and it's not done yet, U.S. CEO says
August 30, 2021
Clinical Oncology News
FDA Approves Tibsovo for Adjuvant Treatment of IDH1-Mutated Cholangiocarcinoma
August 26, 2021
Fierce Pharma
With fresh FDA nod, Servier branches targeted drug Tibsovo into bile duct cancer
August 26, 2021
Scrip
Tibsovo Approval Is A Stepping Stone For Servier’s Longer-Term Oncology Strategy
January 22, 2021
The Pharma Letter
"Very, very busy" Servier Pharma enough to keep CEO up at night
January 14, 2021
Wall Street Journal
Biotech Startup Acquisitions Jumped in 2020, Leaving VCs Optimistic for New Year
January 12, 2021
Endpoints News
Once aiming to double oncology pipeline, Servier's US branch touts rapid pace in building its foothold in the space
December 21, 2020
STAT
Agios sells cancer business to French drug maker for up to $2 billion, will now focus on inherited diseases
December 21, 2020
Boston Globe
Cambridge biotech Agios to sell oncology business to Boston’s Servier for up to $2 billion
December 21, 2020
Endpoints News
Agios pivots away from oncology, auctioning off cancer pipeline for $2B and shifting the spotlight in restructuring
December 14, 2020
The Long Run with Luke Timmerman
Seeking Impact: Servier's David Lee on The Long Run Podcast
December 4, 2020
Yahoo Finance
Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)
February 5, 2020
Business Insider
The 37-Year-Old CEO of A Major Pharma Company Lays Out the Three-Part Strategy That Drove His Career
June 28, 2019
Healio
Servier Pharmaceuticals Executive Highlights Pipeline, ‘Focus on the Patients’
June 7, 2019
Fierce Pharma
Servier, Armed with Shire Cancer Drugs, Builds Out Vision for U.S. Future
May 13, 2019
Area Development
Servier Pharmaceuticals Opens U.S. Headquarters in Boston, Massachusetts
May 9, 2019
Boston Business Journal
Servier Launches U.S. Cancer Business with Plans to Double Headcount in Next 5 Years
July 20, 2018
Fierce Pharma
Servier Picks Shire Executive to Run U.S. Business Being Built Out of Deal for Shire’s Oncology Unit
June 8, 2018
Endpoints News
After Snatching Up Shire's Cancer Unit, French Pharma Giant Servier to Expand US Presence with Kendall Square Innovation Office
More from Servier
Research & Development
We invest in innovative research and development through our own development or partnerships to best address the unmet needs of patients.
Learn MoreClinical Trials
We strive to have consistent and concise transparency throughout all our clinical trials and research and development for the benefit of our patients.
Learn MoreAbout Us
Servier Pharmaceuticals is a privately held pharmaceutical company focused on Oncology. Everything we do is to bring the promise of tomorrow to the patients we serve.
Learn More